Ray Ryan Santos, MD
Internal Medicine · Hoboken, NJNPI 1821241381
Payments from drug & device makers
Across 89 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$239
- Gilead$193
- Cranial Technologies, Inc$181
- Exact Sciences$137
- Sanofi Pasteur Inc.$135
- Pfizer$108
- plus $472 from 17 others
What the payments were for
- Food & beverage$1,464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $239 |
| Gilead | 14 | $193 |
| Cranial Technologies, Inc | 12 | $181 |
| Exact Sciences | 7 | $137 |
| Sanofi Pasteur Inc. | 8 | $135 |
| Pfizer | 7 | $108 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Merck | 4 | $59 |
| Genentech USA, Inc. | 4 | $51 |
| Lilly USA, LLC | 3 | $41 |
| Boston Scientific | 1 | $33 |
| Biogen | 1 | $27 |
| Dermira, Inc. | 2 | $25 |
| Abbott | 1 | $22 |
| Alk-abello, Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Amgen | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
How this compares
$1,464 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 24 | $970 |
| Ciclopirox | 15 | $742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $589 |
| Atorvastatin Calcium | 17 | $330 |
| Cefdinir | 17 | $239 |
| Amlodipine Besylate | 23 | $226 |
| Metformin Hcl | 22 | $200 |
| Fluticasone Propionate | 11 | $172 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $142 |
| Amoxicillin | 43 | $132 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $91 |
| Doxycycline Monohydrate | 11 | $90 |
| Azithromycin | 35 | $83 |
| Cephalexin | 15 | $81 |
| Mupirocin | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Hoboken
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.